The Effects of Resveratrol Supplementation on Endothelial Function and Blood Pressures Among Patients with Metabolic Syndrome and Related Disorders: A Systematic Review and Meta-Analysis of Randomized Controlled Trials

Abstract

Introduction

There are current trials investigating the effect of resveratrol supplementation on endothelial function and blood pressures among patients with metabolic syndrome (MetS); however, the findings are controversial.

Aim

This systematic review and meta-analysis of randomized controlled trials (RCTs) were carried out to summarize the effects of resveratrol supplementation on endothelial activation and blood pressures among patients with MetS and related disorders.

Methods

We searched systematically online databases including: PubMed-Medline, Embase, ISI Web of Science and Cochrane Central Register of Controlled Trials until October, 2018. Two independent authors extracted data and assessed the quality of included articles. Data were pooled using the fixed- or random-effects model and considered as standardized mean difference (SMD) with 95% confidence intervals (95% CI).

Results

Out of 831 electronic citations, 28 RCTs (with 33 findings reported) were included in the meta-analyses. The findings showed that resveratrol intervention significantly increased flow-mediated dilatation (FMD) levels (SMD 1.77; 95% CI 0.25, 3.29; P = 0.02; I2: 96.5). However, resveratrol supplements did not affect systolic blood pressure (SBP) (SMD − 0.27; 95% CI − 0.57, 0.03; P = 0.07; I2: 88.9) and diastolic blood pressure (DBP) (SMD − 0.21; 95% CI − 0.52, 0.11; P = 0.19; I2: 89.8).

Conclusions

Resveratrol supplementation significantly increased FMD among patients with MetS and related disorders, but did not affect SBP and DBP. Additional prospective studies are needed to investigate the effect of resveratrol supplementation on endothelial function and blood pressures, using higher-dose of resveratrol with longer durations.

This is a preview of subscription content, access via your institution.

Fig. 1
Fig. 2
Fig. 3

Abbreviations

DBP:

Diastolic blood pressures

FMD:

Flow-mediated dilation

MetS:

Metabolic syndrome

NAFLD:

Non-alcoholic fatty liver disease

HTN:

Hypertension

SBP:

Systolic blood pressure

T2DM:

Type 2 diabetes mellitus

References

  1. 1.

    Belin de Chantemele EJ, Stepp DW. Influence of obesity and metabolic dysfunction on the endothelial control in the coronary circulation. J Mol Cell Cardiol. 2012;52:840–7.

    Article  CAS  PubMed  Google Scholar 

  2. 2.

    Ribeiro S, Garrido P, Fernandes J, Vala H, Rocha-Pereira P, Costa E, et al. Impaired renal endothelial nitric oxide synthase and reticulocyte production as modulators of hypertension induced by rHuEPO in the rat. Life Sci. 2016;151:147–56.

    Article  CAS  PubMed  Google Scholar 

  3. 3.

    Celik T, Berdan ME, Iyisoy A, Kursaklioglu H, Turhan H, Kilic S, et al. Impaired coronary collateral vessel development in patients with proliferative diabetic retinopathy. Clin Cardiol. 2005;28:384–8.

    Article  PubMed  Google Scholar 

  4. 4.

    Fatehi-Hassanabad Z, Chan CB, Furman BL. Reactive oxygen species and endothelial function in diabetes. Eur J Pharmacol. 2010;636:8–17.

    Article  CAS  PubMed  Google Scholar 

  5. 5.

    Niswender K. Diabetes and obesity: therapeutic targeting and risk reduction - a complex interplay. Diabetes Obes Metab. 2010;12:267–87.

    Article  PubMed  Google Scholar 

  6. 6.

    Krentz AJ. Lipoprotein abnormalities and their consequences for patients with type 2 diabetes. Diabetes Obes Metab. 2003;5(Suppl 1):S19–27.

    Article  CAS  PubMed  Google Scholar 

  7. 7.

    Bonnefont-Rousselot D. Resveratrol and cardiovascular diseases. Nutrients. 2016;8:250.

    Article  CAS  PubMed Central  Google Scholar 

  8. 8.

    Lin YC, Chen LH, Varadharajan T, Tsai MJ, Chia YC, Yuan TC, et al. Resveratrol inhibits glucose-induced migration of vascular smooth muscle cells mediated by focal adhesion kinase. Mol Nutr Food Res. 2014;58:1389–401.

    Article  CAS  PubMed  Google Scholar 

  9. 9.

    El-Mowafy AM, Alkhalaf M, El-Kashef HA. Resveratrol reverses hydrogen peroxide-induced proliferative effects in human coronary smooth muscle cells: a novel signaling mechanism. Arch Med Res. 2008;39:155–61.

    Article  CAS  PubMed  Google Scholar 

  10. 10.

    Wong RH, Berry NM, Coates AM, Buckley JD, Bryan J, Kunz I, et al. Chronic resveratrol consumption improves brachial flow-mediated dilatation in healthy obese adults. J Hypertens. 2013;31:1819–27.

    Article  CAS  PubMed  Google Scholar 

  11. 11.

    Fujitaka K, Otani H, Jo F, Jo H, Nomura E, Iwasaki M, et al. Modified resveratrol Longevinex improves endothelial function in adults with metabolic syndrome receiving standard treatment. Nutr Res. 2011;31:842–7.

    Article  CAS  PubMed  Google Scholar 

  12. 12.

    Marques B, Trindade M, Aquino JCF, Cunha AR, Gismondi RO, Neves MF, et al. Beneficial effects of acute trans-resveratrol supplementation in treated hypertensive patients with endothelial dysfunction. Clin Exp Hypertens. 2018;40:218–23.

    Article  CAS  PubMed  Google Scholar 

  13. 13.

    Vors C, Couillard C, Paradis ME, Gigleux I, Marin J, Vohl MC, et al. Supplementation with resveratrol and curcumin does not affect the inflammatory response to a high-fat meal in older adults with abdominal obesity: a randomized, placebo-controlled crossover trial. J Nutr. 2018;148:379–88.

    Article  PubMed  Google Scholar 

  14. 14.

    Bhatt JK, Thomas S, Nanjan MJ. Resveratrol supplementation improves glycemic control in type 2 diabetes mellitus. Nutr Res. 2012;32:537–41.

    Article  CAS  PubMed  Google Scholar 

  15. 15.

    Kjaer TN, Ornstrup MJ, Poulsen MM, Stodkilde-Jorgensen H, Jessen N, Jorgensen JOL, et al. No beneficial effects of resveratrol on the metabolic syndrome: a randomized placebo-controlled clinical trial. J Clin Endocrinol Metab. 2017;102:1642–51.

    Article  PubMed  Google Scholar 

  16. 16.

    van der Made SM, Plat J, Mensink RP. Trans-resveratrol supplementation and endothelial function during the fasting and postprandial phase: a randomized placebo-controlled trial in overweight and slightly obese participants. Nutrients. 2017. https://doi.org/10.3390/nu9060596.

    Article  PubMed  PubMed Central  Google Scholar 

  17. 17.

    Magyar K, Halmosi R, Palfi A, Feher G, Czopf L, Fulop A, et al. Cardioprotection by resveratrol: a human clinical trial in patients with stable coronary artery disease. Clin Hemorheol Microcirc. 2012;50:179–87.

    CAS  PubMed  Google Scholar 

  18. 18.

    Huang H, Chen G, Liao D, Zhu Y, Pu R, Xue X. The effects of resveratrol intervention on risk markers of cardiovascular health in overweight and obese subjects: a pooled analysis of randomized controlled trials. Obes Rev. 2016;17:1329–40.

    Article  CAS  PubMed  Google Scholar 

  19. 19.

    Fogacci F, Banach M, Cicero AFG. Resveratrol effect on patients with non-alcoholic fatty liver disease: a matter of dose and treatment length. Diabetes Obes Metab. 2018;20:1798–9.

    Article  PubMed  Google Scholar 

  20. 20.

    Cicero AFG, Grassi D, Tocci G, Galletti F, Borghi C, Ferri C. Nutrients and nutraceuticals for the management of high normal blood pressure: an evidence-based consensus document. High Blood Press Cardiovasc Prev. 2019;26:9–25.

    Article  CAS  PubMed  Google Scholar 

  21. 21.

    Sahebkar A, Serban C, Ursoniu S, Wong ND, Muntner P, Graham IM, et al. Lack of efficacy of resveratrol on C-reactive protein and selected cardiovascular risk factors—results from a systematic review and meta-analysis of randomized controlled trials. Int J Cardiol. 2015;189:47–55.

    Article  PubMed  Google Scholar 

  22. 22.

    Fogacci F, Tocci G, Presta V, Fratter A, Borghi C, Cicero AFG. Effect of resveratrol on blood pressure: a systematic review and meta-analysis of randomized, controlled, clinical trials. Crit Rev Food Sci Nutr. 2019;59(10):1605–18.

    Article  CAS  PubMed  Google Scholar 

  23. 23.

    Hausenblas HA, Schoulda JA, Smoliga JM. Resveratrol treatment as an adjunct to pharmacological management in type 2 diabetes mellitus—systematic review and meta-analysis. Mol Nutr Food Res. 2015;59:147–59.

    Article  CAS  PubMed  Google Scholar 

  24. 24.

    Liu Y, Ma W, Zhang P, He S, Huang D. Effect of resveratrol on blood pressure: a meta-analysis of randomized controlled trials. Clin Nutr. 2015;34:27–34.

    Article  CAS  PubMed  Google Scholar 

  25. 25.

    Sleight P, Yusuf S, Pogue J, Tsuyuki R, Diaz R, Probstfield J. Blood-pressure reduction and cardiovascular risk in HOPE study. Lancet. 2001;358:2130–1.

    Article  CAS  PubMed  Google Scholar 

  26. 26.

    Liu Z, Song Y, Zhang X, Liu Z, Zhang W, Mao W, et al. Effects of trans-resveratrol on hypertension-induced cardiac hypertrophy using the partially nephrectomized rat model. Clin Exp Pharmacol Physiol. 2005;32:1049–54.

    Article  PubMed  Google Scholar 

  27. 27.

    Miatello R, Vazquez M, Renna N, Cruzado M, Zumino AP, Risler N. Chronic administration of resveratrol prevents biochemical cardiovascular changes in fructose-fed rats. Am J Hypertens. 2005;18:864–70.

    Article  CAS  PubMed  Google Scholar 

  28. 28.

    Cicero AFG, Fogacci F, Colletti A. Food and plant bioactives for reducing cardiometabolic disease risk: an evidence based approach. Food Funct. 2017;8:2076–88.

    Article  CAS  PubMed  Google Scholar 

  29. 29.

    Timmers S, Konings E, Bilet L, Houtkooper RH, van de Weijer T, Goossens GH, et al. Calorie restriction-like effects of 30 days of resveratrol supplementation on energy metabolism and metabolic profile in obese humans. Cell Metab. 2011;14:612–22.

    Article  CAS  PubMed  Google Scholar 

  30. 30.

    Anton SD, Embry C, Marsiske M, Lu X, Doss H, Leeuwenburgh C, et al. Safety and metabolic outcomes of resveratrol supplementation in older adults: results of a twelve-week, placebo-controlled pilot study. Exp Gerontol. 2014;57:181–7.

    Article  CAS  PubMed  Google Scholar 

  31. 31.

    Chachay VS, Macdonald GA, Martin JH, Whitehead JP, O’Moore-Sullivan TM, Lee P, et al. Resveratrol does not benefit patients with nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol. 2014;12:2092.e1-6–2103.e1-6.

    Article  CAS  Google Scholar 

  32. 32.

    Chen S, Zhao X, Ran L, Wan J, Wang X, Qin Y, et al. Resveratrol improves insulin resistance, glucose and lipid metabolism in patients with non-alcoholic fatty liver disease: a randomized controlled trial. Dig Liver Dis. 2015;47:226–32.

    Article  CAS  PubMed  Google Scholar 

  33. 33.

    Faghihzadeh F, Adibi P, Hekmatdoost A. The effects of resveratrol supplementation on cardiovascular risk factors in patients with non-alcoholic fatty liver disease: a randomised, double-blind, placebo-controlled study. Br J Nutr. 2015;114:796–803.

    Article  CAS  PubMed  Google Scholar 

  34. 34.

    Fodor K, Tit DM, Pasca B, Bustea C, Uivarosan D, Endres L, et al. Long-term resveratrol supplementation as a secondary prophylaxis for stroke. Oxid Med Cell Longev. 2018;2018:4147320.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  35. 35.

    Heeboll S, Kreuzfeldt M, Hamilton-Dutoit S, Kjaer Poulsen M, Stodkilde-Jorgensen H, Moller HJ, et al. Placebo-controlled, randomised clinical trial: high-dose resveratrol treatment for non-alcoholic fatty liver disease. Scand J Gastroenterol. 2016;51:456–64.

    Article  CAS  PubMed  Google Scholar 

  36. 36.

    Imamura H, Yamaguchi T, Nagayama D, Saiki A, Shirai K, Tatsuno I. Resveratrol Ameliorates arterial stiffness assessed by cardio-ankle vascular index in patients with type 2 diabetes mellitus. Int Heart J. 2017;58:577–83.

    Article  CAS  PubMed  Google Scholar 

  37. 37.

    Kantartzis K, Fritsche L, Bombrich M, Machann J, Schick F, Staiger H, et al. Effects of resveratrol supplementation on liver fat content in overweight and insulin-resistant subjects: a randomized, double-blind, placebo-controlled clinical trial. Diabetes Obes Metab. 2018;20:1793–7.

    Article  CAS  PubMed  Google Scholar 

  38. 38.

    Khodabandehloo H, Seyyedebrahimi S, Esfahani EN, Razi F, Meshkani R. Resveratrol supplementation decreases blood glucose without changing the circulating CD14(+)CD16(+) monocytes and inflammatory cytokines in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled study. Nutr Res. 2018;54:40–51.

    Article  CAS  PubMed  Google Scholar 

  39. 39.

    Korsholm AS, Kjær TN, Ornstrup MJ, Pedersen SB. Comprehensive metabolomic analysis in blood, urine, fat, and muscle in men with metabolic syndrome: a randomized, placebo-controlled clinical trial on the effects of resveratrol after four months’ treatment. Int J Mol Sci. 2017;18:554.

    Article  CAS  PubMed Central  Google Scholar 

  40. 40.

    Kumar BJ, Joghee NM. Resveratrol supplementation in patients with type 2 diabetes mellitus: a prospective, open label, randomized controlled trial. Int Res J Pharm. 2013;4:246–9.

    Article  CAS  Google Scholar 

  41. 41.

    Mansur AP, Roggerio A, Goes MFS, Avakian SD, Leal DP, Maranhao RC, et al. Serum concentrations and gene expression of sirtuin 1 in healthy and slightly overweight subjects after caloric restriction or resveratrol supplementation: a randomized trial. Int J Cardiol. 2017;227:788–94.

    Article  PubMed  Google Scholar 

  42. 42.

    Mendez-del Villar M, Gonzalez-Ortiz M, Martinez-Abundis E, Perez-Rubio KG, Lizarraga-Valdez R. Effect of resveratrol administration on metabolic syndrome, insulin sensitivity, and insulin secretion. Metab Syndr Relat Disord. 2014;12:497–501.

    Article  CAS  PubMed  Google Scholar 

  43. 43.

    Movahed A, Nabipour I, Lieben Louis X, Thandapilly SJ, Yu L, Kalantarhormozi M, et al. Antihyperglycemic effects of short term resveratrol supplementation in type 2 diabetic patients. Evid Based Complement Alternat Med. 2013. https://doi.org/10.1155/2013/851267.

    Article  PubMed  PubMed Central  Google Scholar 

  44. 44.

    Poulsen MM, Vestergaard PF, Clasen BF, Radko Y, Christensen LP, Stodkilde-Jorgensen H, et al. High-dose resveratrol supplementation in obese men: an investigator-initiated, randomized, placebo-controlled clinical trial of substrate metabolism, insulin sensitivity, and body composition. Diabetes. 2013;62:1186–95.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  45. 45.

    Seyyedebrahimi S, Khodabandehloo H, Nasli Esfahani E, Meshkani R. The effects of resveratrol on markers of oxidative stress in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled clinical trial. Acta Diabetol. 2018;55:341–53.

    Article  CAS  PubMed  Google Scholar 

  46. 46.

    Simental-Mendia LE, Guerrero-Romero F. Effect of resveratrol supplementation on lipid profile in subjects with dyslipidemia: a randomized double-blind, placebo-controlled trial. Nutrition. 2018;58:7–10.

    Article  CAS  PubMed  Google Scholar 

  47. 47.

    van der Made SM, Plat J, Mensink RP. Resveratrol does not influence metabolic risk markers related to cardiovascular health in overweight and slightly obese subjects: a randomized, placebo-controlled crossover trial. PloS one. 2015;10:e0118393.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  48. 48.

    Biesinger S, Michaels HA, Quadros AS, Qian Y, Rabovsky AB, Badger RS, et al. A combination of isolated phytochemicals and botanical extracts lowers diastolic blood pressure in a randomized controlled trial of hypertensive subjects. Eur J Clin Nutr. 2016;70:10–6.

    Article  CAS  PubMed  Google Scholar 

  49. 49.

    Bo S, Ponzo V, Ciccone G, Evangelista A, Saba F, Goitre I, et al. Six months of resveratrol supplementation has no measurable effect in type 2 diabetic patients. A randomized, double blind, placebo-controlled trial. Pharmacol Res. 2016;111:896–905.

    Article  CAS  PubMed  Google Scholar 

  50. 50.

    Timmers S, de Ligt M, Phielix E, van de Weijer T, Hansen J, Moonen-Kornips E, et al. Resveratrol as add-on therapy in subjects with well-controlled type 2 diabetes: a randomized controlled trial. Diabetes care. 2016;39:2211–7.

    Article  CAS  PubMed  Google Scholar 

  51. 51.

    Timmers S, Konings E, Bilet L, Houtkooper RH, van de Weijer T, Goossens GH, et al. Calorie restriction-like effects of 30 days of resveratrol supplementation on energy metabolism and metabolic profile in obese humans. Cell metabolism. 2011;14:612–22.

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgements

The present study was supported by a grant from the Vice-chancellor for Research, AUMS, Arak, and Iran.

Funding

The present study was founded by a grant from the Vice Chancellor for Research, Arak University of Medical Sciences, in Iran.

Author information

Affiliations

Authors

Contributions

MA, O-RT, K-BL, RT, ED, FK, HM and MJ contributed in data collection and manuscript drafting. All authors approved the final version for submission. ZA contributed in conception, design, statistical analysis and drafting of the manuscript and supervised the study.

Corresponding authors

Correspondence to Mehri Jamilian or Zatollah Asemi.

Ethics declarations

Ethics approval and consent to participate

This study was considered exempt by the AUMS Institutional Review Board.

Conflict of interest

The authors declare no conflict of interest.

Additional information

This article is part of the topical collection on Nutraceuticals in Hypertension & Cardiovascular Prevention.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Akbari, M., Tamtaji, O.R., Lankarani, K.B. et al. The Effects of Resveratrol Supplementation on Endothelial Function and Blood Pressures Among Patients with Metabolic Syndrome and Related Disorders: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. High Blood Press Cardiovasc Prev 26, 305–319 (2019). https://doi.org/10.1007/s40292-019-00324-6

Download citation

Keywords

  • Resveratrol
  • Endothelial function
  • Blood pressures
  • Metabolic syndrome
  • Meta-analysis